Literature DB >> 3896612

Cyclosporine kinetics in renal transplantation.

R J Ptachcinski, R Venkataramanan, J T Rosenthal, G J Burckart, R J Taylor, T R Hakala.   

Abstract

The pharmacokinetics of cyclosporine were evaluated in 41 recipients of a cadaveric renal transplant. Cyclosporine was taken by mouth (mean dose 14 mg/kg) on one study day and was intravenously infused over 2 hours (mean dose 4.7 mg/kg) on the next study day. Cyclosporine was extracted from whole blood and analyzed by HPLC. After intravenous infusion, cyclosporine exhibited multicompartmental behavior. The mean (+/- SD) terminal disposition rate constant was 0.065 +/- 0.036 hours-1 and the harmonic mean t 1/2 was 10.7 hours. The harmonic mean total body clearance of cyclosporine was 5.73 ml/min/kg and the mean apparent volume of distribution was 4.5 +/- 3.6 L/kg. The absorption of oral cyclosporine was slow and incomplete. Peak blood cyclosporine concentrations (means = 1,103 ng/ml) were reached between 1 and 8 hours after oral dosing (means = 4 hours). The mean relative bioavailability was 27.6% +/- 20%. Oral bioavailability was less than 10% in 17% of our subjects. The absorption and clearance of cyclosporine were highly variable. We conclude that the variability in the kinetics of cyclosporine makes trough blood level monitoring essential in the management of patients who receive renal transplants.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3896612     DOI: 10.1038/clpt.1985.174

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  41 in total

1.  Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses.

Authors:  M O Karlsson; A Lindberg-Freijs
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

Review 2.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

Review 3.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

4.  Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Authors:  Manthena V S Varma; Yurong Lai; Bo Feng; John Litchfield; Theunis C Goosen; Arthur Bergman
Journal:  Pharm Res       Date:  2012-05-26       Impact factor: 4.200

5.  Effect of Chronic Therapy on Absorption and Disposition of Cyclosporine.

Authors:  K Habucky; R Venkataramanan; R J Ptachcinski; G J Burckart; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

6.  A rat model of leptomeningeal human neoplastic xenografts.

Authors:  I Bergman; M Ahdab-Barmada; S S Kemp; J A Griffin; N K Cheung
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

7.  Pharmacokinetics of cyclosporin: influence of rate-duration profile of an intravenous infusion in renal transplant patients.

Authors:  S K Gupta; A Bakran; R W Johnson; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

8.  Interaction between FK 506 and cyclosporine in dogs.

Authors:  Y M Wu; R Venkataramanan; M Suzuki; Y Zhu; H Abdallah; J Emeigh; G J Burckart; V S Warty; J J Fung; S Todo
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation.

Authors:  S Ohlman; A Lindholm; H Hägglund; J Säwe; B D Kahan
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Excretion of cyclosporine and its metabolites in human bile.

Authors:  G J Burckart; T E Starzl; R Venkataramanan; H Hashim; L Wong; P Wang; L Makowka; A Zeevi; R J Ptachcinski; J E Knapp
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.